This cohort study, conducted at a single academic centre in India, emphasizes long-term outcomes by monitoring weight loss and comorbidity improvement in the first 1000 patients undergoing ESG, with a minimum 5-year follow-up.


total of 1000 patients, predominantly females (69%), with a mean age of 41.02 +- 12.8 years and a mean BMI of 34.42 +- 4.86 kg/m2, underwent ESG. Follow-up rates at 1, 2, 3, 4, and 5 years were 90.6%, 77.7%, 70.2%, 67.8%, and 64.2%, respectively. Patients were systematically assessed for primary and secondary outcomes, including total weight loss (TWL) and excess weight loss (EWL).


The mean %TWL at 1,2,3,4 and 5 years was 19.6%, 18.1%, 16.7%, 16.2%, and 16.02%, respectively. Corresponding %EWL were 56.5%, 54.5%, 50.7%, 48.9%, and 47.6%, indicating sustained weight loss. Immediate post-operative complications were primarily minor, with one case of SAE of Bleeding in one patient. No chronic complications or mortality were observed. The mean duration of surgery was 61.96 +- 2.1 min, and the hospital stay was three days, although 85.6% of patients were clinically fit for discharge on the same day, culturally preferring a 3-day stay. Significant improvements were observed in comorbidities, with 51% resolution of T2DM, 73% for HTN, 75% DLP, and 89% remission for OSA.


ESG demonstrates safety and efficacy for treating obesity, providing reliable long-term results for at least five years. Regular multidisciplinary monitoring enhances the quality of life with low perioperative complications. ESG should be considered a reliable option for obesity treatment.